Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AYTU vs ESPR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ESPR Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 8–2 Matrix Metrics)

ESPR Overall Winner 6-Pillar Tally: AYTU 3 – 3 ESPR Matrix Metrics: AYTU 2 – 8 ESPR

As of Nov 16, 2026, Esperion Therapeutics, Inc. (ESPR) is the stronger overall head-to-head candidate over AYTU BioPharma, Inc. (AYTU) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas ESPR carries 60.0/100 (BUY) at $3.18 (10.9x Forward P/E, -8.2% operating margin).

  • Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile ESPR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 63.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AYTU vs ESPR
AYTU NASDAQ
AYTU BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$1.81
+1.69% 1D
Market Cap $19.6M
TTM Revenue $58M
Forward P/E 9.2x
Beta / 30D Vol 0.65β · 35% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 49.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.8%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $1.89 · SMA50: $2.00
ESPR NASDAQ Head-to-Head Winner
Esperion Therapeutics, Inc.
Pharmaceutical Preparations
$3.18
-0.31% 1D
Market Cap $822.0M
TTM Revenue $418M
Forward P/E 10.9x
Beta / 30D Vol 1.86β · 6% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 64.0 Flow 70.0 Mom 70.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (14.5% over 20 days), RSI 64
RSI-14: 63.5 · SMA20: $3.16 · SMA50: $3.10

6-Pillar Scorecard Institutional Category Breakdown (AYTU 3 – 3 ESPR)

Columns: Metric · AYTU · ESPR
1. Valuation Multiples AYTU
Forward P/E 9.2x 10.9x
Trailing P/E 9.2x 4.6x
PEG Ratio N/M N/M
EV / Revenue 0.3x 2.2x
2. Growth & Scale ESPR
Revenue Growth (YoY) +6.4% +23.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $58M $418M
Market Cap $19.6M $822.0M
3. Profitability & Quality ESPR
Gross Margin 64.0% 57.8%
Operating Margin -14.4% -8.2%
Net Profit Margin -24.8% -1.8%
Return on Equity (ROE) -52.5% -260.8%
4. Balance Sheet & Cash Flow AYTU
Cash Generation (TTM) -$1.4M -$18M
Cash Flow Margin -2.4% -4.4%
Net Cash / Leverage $4.9M Net Cash $96M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ESPR
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 12.5% (9th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat AYTU
OpEx & R&D Intensity 78.4% of Rev ($45M) 66.0% of Rev ($276M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AYTU (2) vs ESPR (8)
Institutional Metric AYTU ESPR Criterion Row Edge
Market Capitalization
Scale
$19.6M $822.0M Larger Scale ESPR
Trailing P/E Ratio
Valuation
9.2x 4.6x Lower Multiple ESPR
Forward P/E Ratio
Valuation
9.2x 10.9x Lower Multiple AYTU
Revenue Growth (YoY)
Growth
+6.4% +23.2% Higher Growth ESPR
Operating Margin (TTM)
Profitability
-14.4% -8.2% Higher Margin ESPR
Net Profit Margin
Profitability
-24.8% -1.8% Higher Margin ESPR
Return on Equity (ROE)
Capital Efficiency
-52.5% -260.8% Higher ROE AYTU
52-Week Range Position
Momentum
5% ($2–$3) 68% ($1–$4) Stronger Trend ESPR
Beta / 30D Volatility
Risk Regime
0.65β · 35% Vol 1.86β · 6% Vol Lower Realized Risk ESPR
Unified Institutional Score
Composite Signal
48.9 / 100 (HOLD) 60.0 / 100 (BUY) Higher Composite ESPR
Trailing 12M Revenue (USD)
Operating Scale
$58M $418M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.0% 57.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev N/M PEG · 2.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.4M ($4.9M Net Cash) -$18M ($96M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ESPR +3.44 pp
AYTU: -2.17% · ESPR: +1.27%
3M Horizon ESPR +57.98 pp
AYTU: -12.11% · ESPR: +45.87%
6M Horizon ESPR +3.3 pp
AYTU: -20.49% · ESPR: -17.19%
1Y Horizon AYTU +1.79 pp
AYTU: +9.22% · ESPR: +7.43%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AYTU Revenue ESPR Revenue AYTU Op. Margin ESPR Op. Margin Margin Leader
FY2019 $10M $150M -230.1% -62.8% ESPR
FY2020 $30M $230M -76.5% -53.3% ESPR
FY2021 $70M $80M -89.7% -289.0% AYTU
FY2022 $100M $80M -113.7% -237.8% AYTU
FY2023 $110M $120M -15.9% -133.7% AYTU
FY2024 $70M $330M -2.4% 16.4% ESPR
FY2025 $70M $400M -11.8% 15.0% ESPR
FY2026 $60M N/A -14.4% N/A AYTU

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AYTU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AYTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ESPR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 12.5%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ESPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AYTU Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $19.6M market capitalization and -14.4% operating margin.
OpEx & R&D Reinvestment 78.4% of Rev ($45M)
90D Engineering Disclosures 0 Published
ESPR Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $822.0M market capitalization and -8.2% operating margin.
OpEx & R&D Reinvestment 66.0% of Rev ($276M)
90D Engineering Disclosures 0 Published

Investor FAQ AYTU vs ESPR Key Questions & Quantitative Answers

As of Nov 16, 2026, Esperion Therapeutics, Inc. (ESPR) is the stronger overall head-to-head candidate over AYTU BioPharma, Inc. (AYTU) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas ESPR carries 60.0/100 (BUY) at $3.18 (10.9x Forward P/E, -8.2% operating margin). Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile ESPR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 63.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ESPR leads the Growth & Scale pillar: AYTU posts +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin), compared with ESPR at +23.2% YoY revenue growth and +0.0% YoY earnings growth on $418M TTM revenue (57.8% gross margin, -8.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), AYTU cumulative revenue shifted +500.0% while ESPR shifted +166.7%. In operating R&D and SG&A reinvestment, AYTU deploys 78.4% of Rev ($45M) (0 90-day corporate R&D disclosures) versus 66.0% of Rev ($276M) (0 disclosures) for ESPR.

AYTU screens cheaper on headline valuation multiples. AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin), whereas ESPR trades at 10.9x Forward P/E, 4.6x Trailing P/E, N/M PEG, and 2.2x EV/Revenue (-4.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AYTU (-52.5% ROE) versus ESPR (-260.8% ROE) capital efficiency.

In options market volatility and institutional positioning, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk). By comparison, ESPR carries 12.5% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.86β · 6% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.